114. Non-dystrophic myotonia syndrome Clinical trials / Disease details


Clinical trials : 13 Drugs : 19 - (DrugBank : 5) / Drug target genes : 18 - Drug target pathways : 10

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05639257
(ClinicalTrials.gov)
December 5, 20224/10/2022Treatment of Myotonia - Lamotrigine Versus NamusclaTreatment of Myotonia - Lamotrigine Versus NamusclaNon-Dystrophic MyotoniaDrug: Lamotrigine;Drug: NamusclaGrete Andersen, MDGCP-Copenhagen;Region Capital Denmark;Danish Region;Lupin Atlantis Holdings S.A.;ZiteLabRecruiting18 YearsN/AAll32N/ADenmark
2EUCTR2021-003784-94-DK
(EUCTR)
20/01/202230/11/2021Which treatment are the best to reduce myotonia?Treatment of Myotonia - Lamotrigine versus Namuscla Myotonia Congenita (Becker and Thomsen type), Paramyotonia Congenita, and Hyperkalemic periodic paralysis
MedDRA version: 20.1;Level: LLT;Classification code 10049841;Term: Myotonia congenital;System Organ Class: 100000004850
MedDRA version: 20.1;Classification code 10076440;Term: Hyperkalemic periodic paralysis;System Organ Class: 100000004850;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]
Trade Name: Namuscla
INN or Proposed INN: Mexiletine
Trade Name: Lamotrigin ”Nordic Prime 25 mg
INN or Proposed INN: LAMOTRIGINE
Trade Name: Lamotrigin ”Nordic Prime 50 mg
INN or Proposed INN: LAMOTRIGINE
Trade Name: Lamotrigin ”Nordic Prime 100 mg
INN or Proposed INN: LAMOTRIGINE
Rigshospitalet, department of NeurologyNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
32Phase 3Denmark